docetaxelhttp://www.unboundmedicine.com/medline/ebm/research/docetaxelUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells.http://www.unboundmedicine.com/medline/ebm/record/19926394/full_citation/Id1_inhibitor_of_differentiation_is_a_key_protein_mediating_anti_tumor_responses_of_gamma_tocotrienol_in_breast_cancer_cells_Yap WN, Zaiden N, Tan YL, et al. 
Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells. [JOURNAL ARTICLE]
Cancer Lett 2009 Nov 16.
Abstract | Full Citation | Find Related Articles Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes.http://www.unboundmedicine.com/medline/ebm/record/19925835/full_citation/Polyester_based_micelles_and_nanoparticles_for_the_parenteral_delivery_of_taxanes_Gaucher G, Marchessault RH, Leroux JC 
Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. [JOURNAL ARTICLE]
J Control Release 2009 Nov 16.
Abstract | Full Citation | Find Related Articles Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel.http://www.unboundmedicine.com/medline/ebm/record/19924122/full_citation/Intravenous_to_Oral_Switch_in_Anticancer_Chemotherapy:_A_Focus_on_Docetaxel_and_Paclitaxel_Koolen SL, Beijnen JH, Schellens JH 
Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel. [JOURNAL ARTICLE]
Clin Pharmacol Ther 2009 Nov 18.
Full Citation | Publisher Full Text | Find Related Articles [Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer.]http://www.unboundmedicine.com/medline/ebm/record/19923093/full_citation/[Therapeutic_effect_of_docetaxel_combined_with_oxaliplatin_for_treatment_of_recurrent_epithelial_ovarian_cancer_]Wang J, Han N, Wang HL, et al. 
[Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer.] [JOURNAL ARTICLE]
Nan Fang Yi Ke Da Xue Xue Bao 2009 Nov 20; 29(11):2319-2320.
Abstract | Full CitationGlycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.http://www.unboundmedicine.com/medline/ebm/record/19920820/full_citation/Glycogen_synthase_kinase_3:_a_new_therapeutic_target_in_renal_cell_carcinoma_Bilim V, Ougolkov A, Yuuki K, et al. 
Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. [JOURNAL ARTICLE]
Br J Cancer 2009 Nov 17.
Abstract | Full Citation | Find Related Articles [A Case of Adenocarcinoma of the Lung with a Long-Term Therapeutic Effect Due to S-1 Administered as the Sixth Regimen.]http://www.unboundmedicine.com/medline/ebm/record/19920394/full_citation/[A_Case_of_Adenocarcinoma_of_the_Lung_with_a_Long_Term_Therapeutic_Effect_Due_to_S_1_Administered_as_the_Sixth_Regimen_]Okudera K, Takanashi S, Hayashi A, et al. 
[A Case of Adenocarcinoma of the Lung with a Long-Term Therapeutic Effect Due to S-1 Administered as the Sixth Regimen.] [JOURNAL ARTICLE]
Gan To Kagaku Ryoho 2009 Nov; 36(11):1889-1891.
Abstract | Full Citation | Find Related Articles [Decrease in Prostate Specific Antigen Secretion Correlated with Docetaxel-Induced Growth Inhibition and Apoptosis in Human Prostate Tumor Cells.]http://www.unboundmedicine.com/medline/ebm/record/19920389/full_citation/[Decrease_in_Prostate_Specific_Antigen_Secretion_Correlated_with_Docetaxel_Induced_Growth_Inhibition_and_Apoptosis_in_Human_Prostate_Tumor_Cells_]Noguchi K, Shakuto S, Sakairi T, et al. 
[Decrease in Prostate Specific Antigen Secretion Correlated with Docetaxel-Induced Growth Inhibition and Apoptosis in Human Prostate Tumor Cells.] [JOURNAL ARTICLE]
Gan To Kagaku Ryoho 2009 Nov; 36(11):1863-1870.
Abstract | Full Citation | Find Related Articles Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity.http://www.unboundmedicine.com/medline/ebm/record/19920203/full_citation/Absence_of_Both_Cytochrome_P450_3A_and_P_glycoprotein_Dramatically_Increases_Docetaxel_Oral_Bioavailability_and_Risk_of_Intestinal_Toxicity_van Waterschoot RA, Lagas JS, Wagenaar E, et al. 
Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity. [JOURNAL ARTICLE]
Cancer Res 2009 Nov 17.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Targeted Drug and Gene Delivery Systems for Lung Cancer Therapy.http://www.unboundmedicine.com/medline/ebm/record/19920099/full_citation/Targeted_Drug_and_Gene_Delivery_Systems_for_Lung_Cancer_Therapy_Sundaram S, Trivedi R, Durairaj C, et al. 
Targeted Drug and Gene Delivery Systems for Lung Cancer Therapy. [JOURNAL ARTICLE]
Clin Cancer Res 2009 Nov 17.
Abstract | Full CitationToxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy.http://www.unboundmedicine.com/medline/ebm/record/19918925/full_citation/Toxicity_report_of_a_phase_1/2_dose_escalation_study_in_patients_with_inoperable_locally_advanced_nonsmall_cell_lung_cancer_with_helical_tomotherapy_and_concurrent_chemotherapy_Bral S, Duchateau M, Versmessen H, et al. 
Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. [JOURNAL ARTICLE]
Cancer 2009 Nov 13.
Abstract | Full Citation | Publisher Full Text | Find Related Articles